Gene Activity List

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Gene Compound Experiment Study Pathway Assay Report Bug Request Feature
Gene Activity List
You are on Page 33 of 50:
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
Gene Compound Assay Inh Ic50 Ki View
sodium channel, nonvoltage-gated 1, delta CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, nonvoltage-gated 1 alpha CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, voltage-gated, type X, alpha CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, voltage-gated, type IX, alpha CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, voltage gated, type VIII, alpha CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, voltage-gated, type VII, alpha CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, voltage-gated, type IV, beta CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, voltage-gated, type IV, alpha CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, voltage-gated, type III, alpha CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
sodium channel, voltage-gated, type II, beta CITALOPRAM Sodium Channel, Site 2 77% 2.641uM 2.409uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 DIPHENHYDRAMINE Calcium Channel Type L, Phenylalkylamine 76% 7.28uM 7.078uM View
5-hydroxytryptamine receptor 6 DISULFIRAM Serotonin 5-HT6 76% 16.001uM 7.429uM View
Sigma-2 Receptor TRIHEXYPHENIDYL Sigma2 76% 3.122uM 1.921uM View
calcium channel, voltage-dependent, beta 3 subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, beta 2 subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, L type, alpha 1S subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, alpha 1F subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, L type, alpha 1D subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, L type, alpha 1C subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, beta 1 subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, gamma subunit 8 METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, gamma subunit 7 METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, gamma subunit 6 METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, gamma subunit 5 METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, gamma subunit 4 METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, gamma subunit 3 METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, gamma subunit 2 METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
calcium channel, voltage-dependent, gamma subunit 1 METHYSERGIDE Calcium Channel Type L, Benzothiazepine 76% 3.559uM 3.164uM View
adrenergic receptor, alpha 2a LEAD (II) ACETATE Adrenergic alpha2A 76% 3.597uM 1.349uM View
5-hydroxytryptamine (serotonin) receptor 2A PROPRANOLOL Serotonin 5-HT2A 76% 1.466uM .419uM View
adrenergic receptor, alpha 2b QUINACRINE Adrenergic alpha2B 76% 1.825uM .833uM View
cholinergic receptor, muscarinic 5 QUINACRINE Muscarinic M5 76% 3.736uM 2.684uM View
histamine receptor H 2 IMIQUIMOD Histamine H2 76% 1.506uM 1.481uM View
adrenergic receptor, alpha 2b SERTRALINE Adrenergic alpha2C 76% 4.477uM .6505uM View
adrenergic receptor, alpha 2c (Non-specific probe) SERTRALINE Adrenergic alpha2C 76% 4.477uM .6505uM View
monoamine oxidase A SELEGILINE Monoamine Oxidase MAOA 76% 2.984uM NoneNone View
monoamine oxidase A SELEGILINE Monoamine Oxidase MAOA 76% 2.984uM NoneNone View
5-hydroxytryptamine (serotonin) receptor 2B SERTRALINE Serotonin 5-HT2B 76% 3.3935uM 2.1595uM View
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 NORGESTREL Serotonin Transporter 76% 1.119uM .595uM View
prostaglandin-endoperoxide synthase 2 NAPROXEN Cyclooxygenase COX-2 76% 17.001uM NoneNone View
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) NAPROXEN Cyclooxygenase COX-2 76% 17.001uM NoneNone View
calcium channel, voltage-dependent, gamma subunit 8 OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, gamma subunit 7 OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, gamma subunit 6 OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, gamma subunit 5 OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, gamma subunit 4 OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, gamma subunit 3 OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, gamma subunit 2 OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, gamma subunit 1 OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, beta 4 subunit OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, beta 3 subunit OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, beta 2 subunit OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, L type, alpha 1S subunit OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, alpha 1F subunit OXICONAZOLE Calcium Channel Type L, Phenylalkylamine 76% 2.7269uM 2.6512uM View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit SIBUTRAMINE Calcium Channel Type L, Benzothiazepine 75% .809uM .719uM View
calcium channel, voltage-dependent, beta 1 subunit SIBUTRAMINE Calcium Channel Type L, Benzothiazepine 75% .809uM .719uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit SIBUTRAMINE Calcium Channel Type L, Benzothiazepine 75% .809uM .719uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit SIBUTRAMINE Calcium Channel Type L, Benzothiazepine 75% .809uM .719uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 SIBUTRAMINE Calcium Channel Type L, Benzothiazepine 75% .809uM .719uM View
calcium channel, voltage-dependent, gamma subunit 8 SIBUTRAMINE Calcium Channel Type L, Benzothiazepine 75% .809uM .719uM View
adrenergic receptor, beta 3 CANDESARTAN Adrenergic beta3 75% 4.3uM 3.2uM View
Cytochrom P450-1A2 monooxygenase ARTEMISININ CYP450-1A2 Inhibition 75% 2uM NoneNone View
adrenergic receptor, alpha 2b DAPIPRAZOLE Adrenergic alpha2B 75% 1.153uM .526uM View
phosphodiesterase 4A, cAMP specific SB-203580 Phosphodiesterase PDE4 75% 11.59uM NoneNone View
phosphodiesterase 4C, cAMP-specific SB-203580 Phosphodiesterase PDE4 75% 11.59uM NoneNone View
phosphodiesterase 4D SB-203580 Phosphodiesterase PDE4 75% 11.59uM NoneNone View
phosphodiesterase 4B, cAMP specific SB-203580 Phosphodiesterase PDE4 75% 11.59uM NoneNone View
sodium channel, nonvoltage-gated 1 beta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type XI, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, nonvoltage-gated 1, gamma NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, nonvoltage-gated 1, delta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
opioid receptor, sigma 1 ASTEMIZOLE Sigma1 73% 2.246uM .944uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, nonvoltage-gated 1 alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type X, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type IX, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage gated, type VIII, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type VII, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type IV, beta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type IV, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type III, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type II, beta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type II, alpha 2 NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type I, beta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type I, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type IV, beta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel associated protein 1 NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel associated protein 2 NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type III, beta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type I, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type IX, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type VII, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
amiloride-sensitive cation channel 5, intestinal NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type III, beta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type XI, alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type I, beta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type 10, alpha polypeptide NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type IV, alpha polypeptide NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type V, alpha polypeptide NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, voltage-gated, type II, beta NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, nonvoltage-gated 1 alpha NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
sodium channel, nonvoltage-gated 1 gamma NISOLDIPINE Sodium Channel, Site 2 75% 7.354uM 6.709uM View
calcium channel, voltage-dependent, gamma subunit 8 CLOMIPHENE Calcium Channel Type L, Dihydropyridine 75% 1.62uM 1.041uM View
calcium channel, voltage-dependent, gamma subunit 7 CLOMIPHENE Calcium Channel Type L, Dihydropyridine 75% 1.62uM 1.041uM View
calcium channel, voltage-dependent, alpha 1F subunit SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
calcium channel, voltage-dependent, L type, alpha 1D subunit SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
calcium channel, voltage-dependent, L type, alpha 1C subunit SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
calcium channel, voltage-dependent, beta 1 subunit SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
calcium channel, voltage-dependent, L type, alpha 1E subunit SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
calcium channel, voltage-dependent, N type, alpha 1B subunit SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
calcium channel, voltage-dependent, alpha2/delta subunit 1 SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
melanocortin 5 receptor SERTRALINE Melanocortin MC5 74% 4.598uM 4.3132uM View
calcium channel, voltage-dependent, gamma subunit 8 SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
calcium channel, voltage-dependent, gamma subunit 7 SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
calcium channel, voltage-dependent, gamma subunit 6 SERTRALINE Calcium Channel Type L, Benzothiazepine 74% 1.468uM 1.3049uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid A receptor, gamma 1 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid A receptor, pi NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
AT hook, DNA binding motif, containing 1 (DBSS) NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid A receptor, theta NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid A receptor, gamma 2 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid A receptor, alpha 2 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid A receptor, alpha 1 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid A receptor, delta NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 NORGESTREL GABAA, Benzodiazepine, Central 74% 2.359uM 1.922uM View
prostaglandin-endoperoxide synthase 1 NIFLUMIC ACID Cyclooxygenase COX-1 74% 1.064uM NoneNone View
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) NIFLUMIC ACID Cyclooxygenase COX-1 74% 1.064uM NoneNone View
adrenergic receptor, alpha 1d (Non-specific probe) OXYMETAZOLINE Adrenergic alpha1D 74% 2.844uM 1.398uM View
adrenergic receptor, alpha 2a ORPHENADRINE Adrenergic alpha2A 74% 2.156uM .809uM View
adrenergic receptor, alpha 2a CADMIUM CHLORIDE Adrenergic alpha2A 74% 6.918uM 2.594uM View
tachykinin receptor 2 CETYLPYRIDINIUM BROMIDE Tachykinin NK2 74% 8.632uM 2.877uM View
androgen receptor CLOBETASOL PROPIONATE Testosterone 74% 3.775uM 2.517uM View
mitogen activated protein kinase 1 SULFASALAZINE Protein Serine/Threonine Kinase, ERK2 74% 6.332uM NoneNone View
mitogen-activated protein kinase 1 SULFASALAZINE Protein Serine/Threonine Kinase, ERK2 74% 6.332uM NoneNone View
5-hydroxytryptamine (serotonin) receptor 5B DROPERIDOL Serotonin 5-HT4 74% 3.789uM .632uM View
5-hydroxytryptamine (serotonin) receptor 4 DROPERIDOL Serotonin 5-HT4 74% 3.789uM .632uM View
phosphodiesterase 4C, cAMP-specific DIPYRIDAMOLE Phosphodiesterase PDE4 74% 1.579uM NoneNone View
phosphodiesterase 4D DIPYRIDAMOLE Phosphodiesterase PDE4 74% 1.579uM NoneNone View
phosphodiesterase 4B, cAMP specific DIPYRIDAMOLE Phosphodiesterase PDE4 74% 1.579uM NoneNone View
chemokine (C-C motif) receptor 2 BENZOTHIAZYL DISULFIDE Chemokine CCR2B 74% 2.405uM .929uM View
5-hydroxytryptamine receptor 6 FLUOXETINE Serotonin 5-HT6 74% 1.661uM .771uM View
adrenergic receptor, alpha 2a DOXEPIN Imidazoline I2, Central 74% 1.839uM 1.226uM View
adrenergic receptor, alpha 2c (Non-specific probe) DOXEPIN Imidazoline I2, Central 74% 1.839uM 1.226uM View
sodium channel, voltage-gated, type IV, beta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel associated protein 1 DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel associated protein 2 DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type III, beta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type I, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type IX, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type VII, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
amiloride-sensitive cation channel 5, intestinal DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type III, beta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type VIII, alpha polypeptide DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type XI, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type I, beta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type 10, alpha polypeptide DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type IV, alpha polypeptide DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type V, alpha polypeptide DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type II, beta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, nonvoltage-gated 1 alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, nonvoltage-gated 1 gamma DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, nonvoltage-gated 1 beta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type 2, alpha 1 polypeptide DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type XI, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, nonvoltage-gated 1, gamma DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, nonvoltage-gated 1, delta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, nonvoltage-gated 1 alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type X, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type IX, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage gated, type VIII, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type VII, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type IV, beta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type IV, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type III, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type II, beta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type II, alpha 2 DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type I, beta DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
sodium channel, voltage-gated, type I, alpha DOXEPIN Sodium Channel, Site 2 74% 2.542uM 2.319uM View
adrenergic receptor, alpha 2a TICLOPIDINE Imidazoline I2, Central 74% 2.239uM 1.493uM View
adrenergic receptor, alpha 2c (Non-specific probe) TICLOPIDINE Imidazoline I2, Central 74% 2.239uM 1.493uM View
Sigma-2 Receptor TICLOPIDINE Sigma2 74% 3.262uM 2.007uM View
Sigma-2 Receptor LABETALOL Sigma2 74% 2.818uM 1.734uM View
Sigma-2 Receptor R-(+)-PROPRANOLOL Sigma2 74% 3.448uM 2.122uM View
5-hydroxytryptamine (serotonin) receptor 2B HALOPERIDOL Serotonin 5-HT2B 74% 2.05uM 1.305uM View